European Society of Cardiology Congress

Cardiology Today and Healio are pleased to offer highlights from the European Society of Cardiology Congress in Paris. Visit this page often for the latest news, video interviews and more. Also follow @CardiologyToday on Twitter for continuing updates.

Meeting News

Sacubitril/valsartan promotes cardiac structure, function improvement in HFrEF

September 2, 2019
PARIS — Sacubitril/valsartan was associated with improvements in cardiac structure and function as well as N-terminal pro-B natriuretic peptide…
Meeting NewsPerspective

HiSTORIC: Troponin I-based risk stratification safely identifies low-risk patients

September 1, 2019
PARIS — Risk stratification thresholds for high-sensitivity cardiac troponin I were able to safely and effectively identify patients with ACS…
Meeting News

Updated ESC guidelines offer new recommendations on lipids, diabetes and more

September 1, 2019
PARIS — The European Society of Cardiology released five new guidelines, which introduce fresh recommendations such as an LDL goal of less than…
Meeting NewsPerspective

THEMIS: Ticagrelor-aspirin DAPT may benefit selected patients with diabetes, stable CAD

September 1, 2019
PARIS — Ticagrelor added to low-dose aspirin reduced the incidence of ischemic events in patients with stable CAD and diabetes without a…
Meeting NewsPerspective

Complete revascularization superior to culprit lesion-only PCI for STEMI, multivessel CAD: COMPLETE

September 1, 2019
PARIS — Complete revascularization was superior to culprit lesion-only PCI for reducing risk for CV death or MI in patients with STEMI and…
Meeting NewsPerspective

DAPA-HF: Dapagliflozin offers new approach to treatment of HFrEF, even without diabetes

September 1, 2019
PARIS — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening HF and CV death when added to standard therapy in patients…
Meeting NewsPerspective

PARAGON-HF: Sacubitril/valsartan misses primary endpoint for HFpEF; may still provide insight into unmet need

September 1, 2019
PARIS — Sacubitril/valsartan did not reduce the rate of hospitalizations for CV-related death and HF in patients with HF with preserved…
Meeting News

POPular AGE: Clopidogrel remains an option for elderly with ACS

August 31, 2019
PARIS — New data from the POPular AGE study support the use of clopidogrel over ticagrelor and prasugrel, based on significant reduction in…
Meeting News

Aspirin fails to benefit elderly patients for CVD prevention

August 31, 2019
PARIS — Aspirin did not benefit older patients for the primary prevention of CVD, according to a new analysis from the ASPREE trial presented…
Meeting NewsPerspective

Cardioversion with maximum-fixed shocks confers better outcomes vs. low-escalating energy shocks

August 31, 2019
PARIS — Cardioversion with maximum-fixed energy shocks was more effective than low-escalating energy shocks for the treatment of patients with…